Damora Therapeutics, Inc. (DMRA)

Market Cap	1.69B +42,265.6%
Revenue (ttm)	n/a
Net Income	-241.25M
EPS	-9.88
Shares Out	61.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,810
Open	28.77
Previous Close	29.17
Day's Range	27.36 - 29.29
52-Week Range	2.45 - 38.33
Beta	1.47
Analysts	Strong Buy
Price Target	44.67 (+63.27%)
Earnings Date	Aug 10, 2026

About DMRA

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DMRA
• Website: https://www.damoratx.com

Analyst Summary

According to 10 analysts, the average rating for DMRA stock is "Strong Buy." The 12-month stock price target is $44.67, which is an increase of 63.27% from the latest price.

Price Target

$44.67

(63.27% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 9, 2026

Data Sources Report a data error